×
About 16,463 results

Allergen-Specific Immunotherapy During Pregnancy Appears Safe for Babies
https://www.medscape.com/viewarticle/974255

May 20th, 2022 - NEW YORK (Reuters Health) - Maintaining allergen-specific immunotherapy (AIT) during pregnancy shows no evidence of raising the risk of congenital malformations or other adverse pregnancy outcomes, according to a nationwide study from Sweden. Although a few earlier studies evaluating AIT in pregnant women have come to similar conclusions, they were small "and guidelines continue to recommend ag...

H pylori May Undermine Immunotherapy Response in Gastric Cancer
https://www.medscape.com/viewarticle/974351

May 20th, 2022 - The study was published on researchsquare.com as a preprint and has not yet been peer reviewed. Key Takeaways Patients with advanced gastric cancer who have active Helicobacter pylori infections were less likely to respond to anti-PD-1 antibody therapy than H pylori–negative patients. Those with active H pylori infections also demonstrated shorter progression-free survival (PFS) and overall sur...

Gynecologic Cancer Studies: What to Look for at ASCO 2022
https://www.medscape.com/viewarticle/973898

May 20th, 2022 - This transcript has been edited for clarity. I'm Maurie Markman from Cancer Treatment Centers of America. I would like to briefly comment on the abstracts that have been released for the American Society of Clinical Oncology (ASCO) meeting coming up next month in Chicago and specifically the gynecologic oncology track. It's going to be a very interesting series of sessions. There's an oral abst...

Experts Urge Stopping Melanoma Trial Because of Failure and Harm
https://www.medscape.com/viewarticle/974244

May 19th, 2022 - New results from a phase 3 clinical trial may shut the door on the addition of progressive death–1 or PD–ligand 1 inhibitors to the combination of BRAF and MEK inhibitors for the treatment of BRAF V600–mutated melanoma. The approach seemed promising, given the efficacy of PD-1 and PD-L1 inhibitors in metastatic melanoma, and the relatively short response times to BRAF and MEK inhibitors could p...

Cancer Patients Unaware of Their Increased Thrombosis Risk
https://www.medscape.com/viewarticle/974066

May 16th, 2022 - More than 70% of cancer patients do not know that they are at greater risk of deep vein thrombosis (DVT) than the general population. It is up to their physician to discuss this with them. This link is explained by the authors of an article in Cancer Treatment and Research Communications that reports results of a survey carried out by the European Cancer Patient Coalition (ECPC). "The aim of th...

New Class of Cancer Drugs Down, Not Out, After Roche Trial Setback: Analysts
https://www.medscape.com/viewarticle/973822

May 12th, 2022 - LONDON (Reuters) - The fresh blow to Roche's hopes in a closely watched class of cancer immunotherapies cast a long shadow across the crowded field on Wednesday, but the latest setback is not the end of the road for these oncology treatments, analysts say. Roche said an interim analysis of an ongoing clinical trial showed that its experimental drug, tiragolumab, failed to meaningfully slow dise...

Oncology Case Challenge: A 45-Year-Old Father Seeking Vasectomy Has Alarming Findings
https://www.medscape.com/viewarticle/973582

May 10th, 2022 - Editor's Note: The Case Challenge series includes difficult-to-diagnose conditions, some of which are not frequently encountered by most clinicians but are nonetheless important to accurately recognize. Test your diagnostic and treatment skills using the following patient scenario and corresponding questions. If you have a case that you would like to suggest for a future Case Challenge, please ...

COVID Booster Mounts 'Brisk' Response in Patients With Cancer
https://www.medscape.com/viewarticle/973545

May 6th, 2022 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. New data shed light on the durability of antibody responses to SARS-CoV-2 vaccines and the impact of booster doses for patients with cancer undergoing systemic therapy or who have received a stem cell transplant (SCT). In a cross-sectional study of 453 such patients, anti-SARS-CoV-2 spike protei...

Q&A With Hubert (Hugh) Greenway, MD
https://www.medscape.com/viewarticle/973517

May 5th, 2022 - Anyone who practices Mohs micrographic surgery is likely to know the name Hugh Greenway, MD, the longtime head of Mohs and dermatologic surgery at Scripps Clinic in San Diego, who was also recently selected as program director for cutaneous oncology at Scripps MD Anderson Cancer Center in San Diego. He is also a former president of the American College of Mohs Surgery. After earning his medical...

Considering Novel Therapy for HER2+ Metastatic Breast Cancer
https://www.onclive.com/view/considering-novel-therapy-for-her2-metastatic-breast-cancer

May 2nd, 2022 - Transcript: Neil Iyengar, MD: [This has been a] great discussion. I’ve enjoyed going through those cases with you. We’ll start to wrap up and summarize our discussion. We had a nice discussion about how the landscape for HER2 [human epidermal growth factor receptor 2]–positive disease has been changing. I’ll summarize by reiterating what we’ve heard. We still have the current standard of care i...

IO Therapy in NSCLC With Concomitant KRAS/TP53 Mutations
https://www.onclive.com/view/io-therapy-in-nsclc-with-concomitant-kras-tp53-mutations

May 2nd, 2022 - Transcript: Meghan J. Mooradian, MD: TP53 is a very common mutation that we’re often finding in our next-generation sequencing. These mutations can be found in isolation, and they can often co-occur with mutations such as KRAS. These mutations do not often sway clinicians one way or another to use immunotherapy [IO] or immunotherapy plus chemotherapy combinations. What we have seen is that the...

Poor Outcomes With IO Therapy in NSCLC With Concomitant KRAS/STK11 or KRAS/KEAP1 Mutations
https://www.onclive.com/view/poor-outcomes-with-io-therapy-in-nsclc-with-concomitant-kras-stk11-or-kras-keap1-mutations

May 2nd, 2022 - Transcript: Meghan J. Mooradian, MD: I think there’s an important question of, is there a role for PD-1 or PD-L1 inhibitors and the treatment of non–small cell lung cancer in patients with STK11 or KEAP1 mutations when they occur alone, specifically when they are not occurring in the context of a KRAS mutation? What we’ve seen is though STK11 and KEAP1 commonly occur with KRAS, these mutations...

FDA Issues Complete Response Letter for Nasopharyngeal Carcinoma Drug Toripalimab
https://www.medscape.com/viewarticle/973242

May 2nd, 2022 - Drug manufacturers Coherus and Junshi Biosciences announced today that the US Food and Drug Administration (FDA) has issued a complete response letter for the biologics license application (BLA) for toripalimab for the treatment of advanced recurrent or metastatic nasopharyngeal carcinoma (NPC). The complete response letter requested a "quality process change" that the drug companies say "is re...

Impact of Adjuvant Therapy on Treatment Selection in Advanced RCC
https://www.onclive.com/view/impact-of-adjuvant-therapy-on-treatment-selection-in-advanced-rcc

Apr 28th, 2022 - Tian Zhang, MD: Dr Braun, how has the use of adjuvant therapy has impacted our treatment decisions and subsequent therapy, specifically patients progressing after adjuvant pembrolizumab? David Braun, MD, PhD: That’s a great question. Truthfully, it’s a difficult question. I don’t think we know the answer. There are some general principles we can think about, but for someone who’s progressed ...

Combination Sitravatinib and Nivolumab Boosts Outcomes in Advanced Kidney Cancer
https://www.medscape.com/viewarticle/972855

Apr 28th, 2022 - NEW YORK (Reuters Health) - In patients with advanced clear cell renal cell carcinoma (ccRCC), an optimal sitravatinib dose combined with a fixed dose of nivolumab improved outcomes in a phase 1-2 trial. "A surprising finding was that patients treated with the higher dose of sitravatinib (120 mg) consistently reported better quality of life after three months of therapy compared with patients t...

Adjuvant Atezolizumab Approaches EU Approval for High-Risk NSCLC With PD-L1 of ≥50%
https://www.onclive.com/view/adjuvant-atezolizumab-approaches-eu-approval-for-high-risk-nsclc-with-pd-l1-of-50-

Apr 22nd, 2022 - The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion supporting the approval of adjuvant atezolizumab (Tecentriq), after complete resection and platinum-based chemotherapy, in adult patients with non–small cell lung cancer (NSCLC) with a high risk of recurrence and whose tumors express PD-L1 of 50% or higher and do not harbor EGFR ...

Nivolumab Plus Relatlimab Aims to Become Primary Treatment Option for Advanced Melanoma
https://www.onclive.com/view/nivolumab-plus-relatlimab-aims-to-become-primary-treatment-option-for-advanced-melanoma

Apr 21st, 2022 - The addition of novel anti–LAG-3 antibody relatlimab-rmbw to antiPD-1 antibody nivolumab offers treatment-naïve patients with unresectable or metastatic melanoma an efficacious and tolerable immunotherapy treatment option. The FDA approved the combination of nivolumab and relatlimab-rmbw (Opdualag) for adult and pediatric patients 12 years or older with unresectable or metastatic melanoma.1 Th...

Personalized Medicine Evolves With CDK4/6 Inhibitors, Immunotherapy, and ADCs in Breast Cancer
https://www.onclive.com/view/personalized-medicine-evolves-with-cdk4-6-inhibitors-immunotherapy-and-adcs-in-breast-cancer

Apr 21st, 2022 - The CDK4/6 inhibitors ribociclib (Kisqali), palbociclib (Ibrance), and abemaciclib (Verzenio) have been integrated into clinical practice for patients with metastatic hormone receptor (HR)–positive breast cancer. Because all 3 agents have demonstrated progression-free survival (PFS) benefits in clinical trials, each has found a role in practice, according to Hadeel Assad, MD, who added adverse ...

Pembrolizumab/Lenvatinib Plus Chemo May Represent “Powerful” Option for NSCLC
https://www.onclive.com/view/pembrolizumab-lenvatinib-plus-chemo-may-represent-powerful-option-for-nsclc

Apr 20th, 2022 - Although the addition of lenvatinib (Lenvima) to pembrolizumab (Keytruda) did not improve overall survival vs pembrolizumab alone in the first-line treatment of patients with metastatic, PD-L1–positive non–small cell lung cancer (NSCLC) in the phase 3 LEAP-007 trial (NCT03829332),1 combining this immunotherapy/TKI regimen with chemotherapy could serve to improve outcomes for these patients, acc...

Cancer Groundshot: From Blog Post to ASCO Session
https://www.medscape.com/viewarticle/972098

Apr 20th, 2022 - "Cancer Moonshot" is almost a household phrase in the US. When then-Vice President Joe Biden first announced the $1.8 billion initiative in 2016, he set the lofty goal to "end cancer as we know it." The major focus of the Cancer Moonshot was genomics, precision therapy, immunotherapy, and artificial intelligence. At that time, I was a trainee in medical oncology and was not yet active on social...